Scholarlink

<p>Edaravone dexborneol (ED), a combination of edaravone and ( +)-borneol, offers antioxidant and anti-inflammatory neuroprotection in acute ischemic stroke (AIS). Prior meta-analyses were limited by small sample sizes, inclusion of observational studies, and lack of subgroup evaluations. To assess the efficacy and safety of ED in AIS, including patients undergoing endovascular thrombectomy (EVT). We systematically reviewed randomized controlled trials (RCTs) up to February 2026 using PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. The primary outcome was excellent functional recovery (mRS 0–1 at 90&#xa0;days). Secondary outcomes included mRS 0–2 and 3–6, NIHSS changes, mortality, hemorrhagic complications, cognitive and functional measures, and adverse events. Risk of bias and certainty of evidence were evaluated using RoB 2 and GRADE. Eight RCTs (<i>n =</i> 4,197) were included. ED significantly improved mRS 0–1 (RR = 1.14; 95% CI: 1.07–1.20) and mRS 0–2 (RR = 1.06; 95% CI: 1.02–1.11), reduced poor outcomes (mRS 3–6; RR = 0.87; 95% CI: 0.79–0.94) and hemorrhagic transformation (RR = 0.55; 95% CI: 0.38–0.81), without increasing adverse events or mortality. Subgroup analyses suggested benefits across most demographics, although effects on mRS 0–1 were less pronounced in EVT-only patients. ED appears to improve functional outcomes and reduce hemorrhagic complications in AIS, with a favorable safety profile. However, findings should be interpreted cautiously due to population and trial limitations, and further multicentre studies are needed to confirm efficacy, particularly in EVT and high-risk subgroups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Edaravone dexborneol in acute ischemic stroke: a systematic review and meta-analysis of randomized trials with clinical and thrombectomy-specific subgroup analyses

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Eman Tariq,
  • Hooriya Ahmed,
  • Tayyaba Ikram Qazi,
  • Abdul Muhaimin,
  • Aleena Amir Malik,
  • Javeria Soomro,
  • Rahimeen Qureshi,
  • Zainab Murtaza,
  • Sarum Ali Khan,
  • Wajeeha Komal,
  • Hadia Tanveer,
  • Rida Ameer,
  • Mahathir Mohammad,
  • Khayyam Haider,
  • Muhammad Faaz Khan,
  • Haris Wazir Khan,
  • Yasir Mehmood,
  • Asia Batool,
  • Sajjad Ghanim Al-Badri,
  • Muhammad Huzaifa Khattak,
  • Bilal Wazir Khan

摘要

Edaravone dexborneol (ED), a combination of edaravone and ( +)-borneol, offers antioxidant and anti-inflammatory neuroprotection in acute ischemic stroke (AIS). Prior meta-analyses were limited by small sample sizes, inclusion of observational studies, and lack of subgroup evaluations. To assess the efficacy and safety of ED in AIS, including patients undergoing endovascular thrombectomy (EVT). We systematically reviewed randomized controlled trials (RCTs) up to February 2026 using PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. The primary outcome was excellent functional recovery (mRS 0–1 at 90 days). Secondary outcomes included mRS 0–2 and 3–6, NIHSS changes, mortality, hemorrhagic complications, cognitive and functional measures, and adverse events. Risk of bias and certainty of evidence were evaluated using RoB 2 and GRADE. Eight RCTs (n = 4,197) were included. ED significantly improved mRS 0–1 (RR = 1.14; 95% CI: 1.07–1.20) and mRS 0–2 (RR = 1.06; 95% CI: 1.02–1.11), reduced poor outcomes (mRS 3–6; RR = 0.87; 95% CI: 0.79–0.94) and hemorrhagic transformation (RR = 0.55; 95% CI: 0.38–0.81), without increasing adverse events or mortality. Subgroup analyses suggested benefits across most demographics, although effects on mRS 0–1 were less pronounced in EVT-only patients. ED appears to improve functional outcomes and reduce hemorrhagic complications in AIS, with a favorable safety profile. However, findings should be interpreted cautiously due to population and trial limitations, and further multicentre studies are needed to confirm efficacy, particularly in EVT and high-risk subgroups.